good morning
[ner:person] [ner:organization]
begin want remind everyone meeting hold [ner:date] term safe_harbor_disclaimer
disclaimer read follow follow discussion may contain certain statement constitute forward look statement within [ner:organization] safe_harbor_provision private securities_litigation_reform_act rule_3b [ner:misc]
although statement represent management good judgment [ner:date] information [ner:date] available statement involve risk uncertainty could cause result differ materially company expectation
would also like ask everyone follow guideline
conference_call will maximum [ner:duration] will begin business_highlight [ner:person] [ner:organization] chief_executive follow question_-_and_-_answer_session
request ask [ner:number] question time will honor request [ner:number] clarification require
will allow everyone ask least [ner:number] question
let [ner:date] turn meeting [ner:person] [ner:organization] chief_executive_officer
okay
thank [ner:person]
welcome everyone
may see press_release want cover highlight [ner:date] open_it_up q&a
record earnings [ner:percent] [ner:date] revenue across entire business [ner:percent]
human_health_category [ner:percent] revenue would [ner:percent] except foreign exchange
bioscience_business [ner:percent] revenue
also able increase gross profit life_science_sector mainly eliminate low margin_product replace high margin_new_product improve productivity new product_growth
[ner:money] revenue budget new product new [ner:date]
focus primarily proprietary product service less extent involve service large pharma
reposition company life_science proceed well
[ner:date] [ner:percent] gross profit come [ner:organization] [ner:percent] [ner:date]
[ner:date] complete [ner:number] acquisition life_science_sector accretive earnings
[ner:number] give new technology_platform build_on [ner:date]
expect will major change business_model way_new_drug_discovery take place way lead compound select optimize clinical trial perform result new different product_approval
really go drive fact cost new drug_delivery must reduce million [ner:money] time must reduce [ner:duration] matter [ner:duration]
involve [ner:date] small way will add product service [ner:date] take advantage major shift
[ner:number] example building [ner:date] would like mention acquisition [ner:location] [ner:organization] [ner:date]
really new technology_platform base enzyme_chemistry
r&d_program run business [ner:duration] cost couple [ner:money] [ner:duration]
[ner:date] begin pay_off
develop new patent route taxol_side_chain manufacture ship several [ner:money] new compound
[ner:person] develop new route control substance use add attention_deficit_disorder
produce [ner:number] kilogram_quantity chiragene_cgmp_pilot_plant large scale_production will [ner:location] [ner:location] business will grow least [ner:money] [ner:duration]
also work chiral compound [ner:location] use enzyme produce new class material call epoxide_hydrolase
will use make new chiral building_block new drug
lastly would like mention demand active pharmaceutical ingredient generic pharmaceutical company continue grow order_backlog time high
many know number_[ner:number] field term number compound active ingredient offer expect add [ner:number] new compound [ner:duration] go forward
[ner:person] [ner:date] open_it_up question
[ner:person] [ner:organization]
[ner:person] will [ner:duration]
begin want remind everyone meeting hold [ner:date] term safe_harbor_disclaimer
follow discussion may contain certain statement constitute forward look statement [ner:organization] safe_harbor_provision private securities_litigation_reform_act rule_3b [ner:misc]
although statement represent management good judgment [ner:date] information [ner:date] available statement involve risk uncertainty could cause result differ materially company expectation
would also like everyone follow guideline conference_call
will maximum [ner:duration]
will begin business_highlight [ner:person] [ner:organization] chief_executive_officer follow question_-_and_-_answer_session
request ask [ner:number] question time will honor request [ner:number] clarification require
will provide access everyone question
[ner:date] let turn meeting [ner:person]
okay
thank [ner:person]
good morning everyone
will take [ner:duration] discuss highlight [ner:date]
see press_release record_earnings [ner:date] [ner:number] [ner:percent] [ner:date]
although strong dollar negatively impact [ner:organization] addition mention experience several customer_overstock_situation addition drop number product deteriorate margin_ass_part continuous product_rationalization_activity
combine product_mix [ner:date] increase margin gross margin [ner:percent] [ner:percent]
lastly category see press_release [ner:organization] [ner:date] behind
next want comment small important transaction make [ner:date]
[ner:ordinal] acquire line zinc_and_chromium_picolinate use human animal nutrition
chemistry nice fit exist pyridine_technology
time will add [ner:money] highly profitable business
go move manufacturing product facility [ner:location] [ner:location]
[ner:ordinal] announce acquisition [ner:organization] technology base company [ner:location]
purchase support entry high throughput_screening_market novel patented luminescent technology
[ner:misc] biowhittaker talk fairly extensively change take place drug_discovery drug_development open way new cell base high throughput_screening_assay test toxicity drug_candidate well select lead will process animal_testing clinical trial
technology provide definitive advantage term sensitivity speed wide dynamic assay_range
[ner:person] already [ner:number] product introduce market several pipeline
plan integrate product service exist bioscience_infrastructure
addition product_sale alone expect grow [ner:money] plan use acquisition foundation bioassay_service_business will build_on
addition [ner:number] acquisition announce supply_agreement cecure proprietary antibacterial formulation food_and_food_processing_equipment
material show dramatic ability eliminate bacterium [ner:location] e._coli listeria
wait [ner:duration] [ner:organization] approve application [ner:date] expect complete [ner:date] case will add expect [ner:money] top line_sale [ner:date]
move different topic
consequence strengthen sale_force [ner:date] [ner:date] see record_number_of_project_opportunity
new product introduce [ner:date] alone expect [ner:money] revenue track achieve
also result several lab run capacity work new project
result expand facility hire chemist
also expand pilot_facility [ner:location] [ner:location] schedule occupy [ner:organization] [ner:date] probably [ner:date] rather [ner:date]
[ner:date] will review [ner:organization] scope phase [ner:number] phase_iii technical center
expect phase [ner:number] approve [ner:date] will provide cgmp_kilo_lab_facility
follow [ner:person] will add cgmp_pilot_plant [ner:organization]
lastly want mention recruit scientist_,_chemist [ner:date] hire another top notch_molecular_scientist dr._[ner:person] will become vice_president r&d [ner:organization]
dr._[ner:person] expert biochemistry cell_biology
experience [ner:organization]
head research_lab [ner:organization] [ner:date] chief_scientific_officer osiris_therapeutics strong reputation convert technology marketable product
secondly hire dr._[ner:person] join [ner:organization] technical_director molecular_biology_products
dr._[ner:person] [ner:date] r&d_group_manager protein_expression [ner:organization]
build business base technology_platform add good person find support growth area
would [ner:date] open_it_up q&a_session
operator
hello welcome
begin want remind everyone meeting hold [ner:date] term safe_harbor_disclaimer
safe_harbor_disclaimer follow discussion may contain certain statement constitute forward look statement [ner:organization] safe_harbor_provision private securities_litigation_reform_act rule_3b [ner:misc]
although statement represent management good judgment [ner:date] information [ner:date] available statement involve risk uncertainty could cause result differ materially company expectation
conference_call_guideline would also like ask everyone follow guideline
conference_call will maximum [ner:duration]
will begin business_highlight mr._[ner:person] question_-_and_-_answer_session
request ask [ner:number] question time will honor request [ner:number] clarification require
will provide access everyone question
instant replay conference_call will available approximately [ner:number] [ner:date] end business [ner:date] call [ner:number] domestic call [ner:number] international
webcast also accessible website www.cambrex.com
please click investor_relations_button
[ner:date] let turn meeting [ner:person] [ner:organization] chairman chief_executive_officer
thank [ner:person] good morning everyone
also join [ner:date] [ner:person] executive vice_president chief_operating_officer
will spend [ner:duration] discuss highlight [ner:date] will open_it_up q&a
see press_release record earnings [ner:date] [ner:percent] [ner:date] pleased performance
impressive accomplishment since know typically soft quarter addition [ner:date] several external factor negatively impact top line_growth profitability
weak euro [ner:number] effect [ner:ordinal] negative impact [ner:misc] sale convert back us_-_dollar_basis secondly allow [ner:misc] competitor significant advantage price
face aggressive pricing_situation competition several active pharmaceutical ingredient area ulcerative colitis animal_health_product x-ray_contrast_media_product
addition currency_translation human health_sector impact growth [ner:percent]
animal health_/_ag specialty_segment experience significant increase raw material_and_energy_cost discuss [ner:date]
change raw material_price [ner:date] alone cost [ner:money] pre-tax
continue pass cost increase lag due price_protection term expect recover [ner:date]
human health_segment_sale typically lumpy quarter quarter combined effect euro postpone order continue shift high margin_product continue lower sale_number particular [ner:number] customer delay [ner:organization] [ner:date] [ner:number] customer process_validation_change complete couple inventory_overstock
finally bioscience_segment supply_problem mention [ner:number] cell_type result [ner:money] [ner:date]
sourcing_problem resolve year_-_end
side exclude [ner:number] product supply_problem base_business balance normal human cell_line achieve [ner:percent] sale
good performance mask couple problem
will [ner:date] open_it_up question
[ner:person] could proceed
good morning everyone
operator note [ner:person] [ner:organization] chief_financial_officer
[ner:person] chief_executive_officer [ner:person] chief_operating_officer [ner:organization]
begin want remind everyone conference_call hold [ner:date] term safe_harbor_disclaimer
follow discussion may contain certain statement constitute forward look statement [ner:organization] safe_harbor_provision private securities_litigation_reform_act rule_3b [ner:misc]
although statement represent management good judgment [ner:date] information [ner:date] available statement involve risk uncertainty could cause result differ materially company expectation
would also like ask everyone follow guideline
conference_call will maximum [ner:duration]
will begin business_highlight [ner:person] question_-_and_-_answer_session
request ask [ner:number] question time will honor request [ner:number] clarification require
will provide access everyone question
also note will instant replay conference_call available approximately [ner:number] [ner:date] will available end business [ner:date] call [ner:number] domestic call [ner:number] international
webcast also accessible website www.cambrex.com
[ner:date] let turn meeting [ner:person] [ner:organization] chairman chief_executive_officer
thank [ner:person] good morning everyone
want spend [ner:duration] discuss highlight [ner:date] comment [ner:date] outlook
[ner:ordinal] pleased [ner:date] able achieve bottom line expectation difficult environment
particularly impressive light exceptionally [ner:date] include y2k pre-buy even though customer deny happen
anticipate [ner:date] also incur rise feedstock_price energy_price currency_effect negatively impact top line_sale profitability
also y2k buy additional effect stock pile pull_down demand [ner:date] throughout [ner:date]
ship [ner:number] new product [ner:ordinal] time [ner:date] continue make strong progress problem_area discuss [ner:date]
set stage growth [ner:date] new product_sale product introduce [ner:date] nearly [ner:money]
expect build foundation throughout [ner:date]
human health report gross sale increase [ner:percent] versus [ner:date]
however add back currency_translation_effect [ner:percent] put increase [ner:number] low end target_growth_range
however normalize y2k_impact almost [ner:money] would place upper end growth_range close [ner:percent]
continue walk away low margin_business considerable less impact [ner:date]
time however euro continue strengthen recover [ner:date] lose business
build innovative pharmaceutical_business strong pipeline new product development_facility full [ner:date] well [ner:date]
provide additional capability [ner:date] announce complete occupy [ner:organization] new facility will hub life_science_product_process_development
complete expansion new product_facility [ner:location] [ner:location] build new large laboratory [ner:location]
generic business introduce [ner:number] new product [ner:date] include wide range cover antiviral tranquilizer beta_-_blocker colitis_treatment antihistamine antibacterial adhd_therapeutics
significant backlog production well [ner:date]
expand geographic marketing_territory demand generic pharmaceutical continue spread country include [ner:location] [ner:location] [ner:location] [ner:location] well country [ner:location]
also [ner:date] announce equity_investment technical collaboration synthon_chiragenics
collaboration include manufacturing_agreement already ship product technical collaboration leverage_synthon [ner:organization] chiral technology
work synthon [ner:duration]
[ner:date] scale_up [ner:number] new pharma_product metric ton_quantity
expect see [ner:number] relationship
bioscience_area grow [ner:number] year_-_over-year continue push_margin_up
[ner:date] [ner:percent] [ner:percent] [ner:date]
sale [ner:date] low margin serum diagnostic product entirely responsible
high growth high margin_product_line remain healthy
reorganize bioscience_business [ner:number] global business_unit bio-research bio-therapeutic business_unit
organization base manage end_market customer back company will enhance entire supply_chain_performance
will able focus new technology speed new product marketplace
coincident new structure put several new seasoned bioscience_executive place
solve sourcing_problem time implement new information_system business_process
see multitude opportunity horizon leverage integrate technology across multiple platform
already see benefit global business_alignment lal_tox_testing_product_line finish [ner:date] strong note lot new product_momentum go [ner:date]
cell_therapy continue strategic long term_growth_area bioscience_unit
agreement company make product late clinical phase_[ner:number] cell base therapeutic
cell base assay also high priority
market_segment_growth expect exceed [ner:percent] per [ner:duration] continue put resource place acquisition lumitech build [ner:money] within [ner:duration]
finally [ner:date] [ner:organization] continue target sale_revenue_growth [ner:percent] bioscience_segment [ner:percent] human health
new technology product cell media cell_-_therapy_bioassay new cell_system will fuel build growth
generic pharma demand will continue expand geographically increase number drug come_off patent will increase yield generic api_growth
also expect enter manufacturing generic biopharmaceutical
use sailing_term feel wind [ner:date] back
raw material_cost decline energy_cost trend_down euro strengthen resolution raw material_supply_problem take care
think really low point specialty_chemical_cycle look excellent exciting [ner:date] sale net income reposition company life_science_arena
operator could [ner:date] open_it_up q&a
welcome
[ner:person] [ner:organization] chief_financial_officer
begin want remind everyone conference_call hold [ner:date] term safe_harbor_disclaimer
disclaimer say follow discussion may contain certain statement constitute forward look statement [ner:organization] safe_harbor_provision [ner:misc] rule_3b [ner:misc]
although statement represent management good judgment [ner:date] information [ner:date] available statement involve risk uncertainty could cause result differ materially company expectation
would also like ask everyone follow guideline
conference_call will maximum [ner:duration]
will begin business_highlight [ner:person] [ner:organization] chairman chief_executive_officer question answer_session
request ask [ner:number] question time will honor request [ner:number] clarification require
will provide access everyone question
instant replay conference_call will available approximately [ner:number] [ner:date] end business [ner:date] call [ner:number] [ner:number] international
webcast also accessible website "www.cambrex.com
[ner:date] let turn meeting [ner:person]
thank [ner:person]
good morning everyone
want spend [ner:duration] discuss highlight [ner:date] [ner:date] outlook
know many call will get q&a [ner:duration]
pleased [ner:date]
net income increase almost [ner:percent] eps increase [ner:percent] compare [ner:date]
come combined effect top line_growth life_science_segment continue margin_improvement reduce interest tax_rate
compare [ner:date] improvement even dramatic
bioscience_segment start [ner:date] strong sale_growth [ner:percent] account currency_impact sale_growth [ner:percent]
increase come predominantly sale cell_system media lal_endotoxin_product market already strong position
[ner:date] organize bioscience_segment [ner:number] global business_group biotherapeutic bioresearch
combination talented new management organization structure enhance customer_focus catalyst double digit_growth
also put behind [ner:organization] cause shortage supply [ner:date] [ner:number] [ner:number] cell_source_problem discuss [ner:date]
backlog resolve mid-quarter [ner:date]
[ner:organization] also start [ner:date] well top line_sale [ner:number] [ner:date]
account currency sale_growth close [ner:percent]
growth sector continue come new product market include instance intermediate [ner:organization] [ner:organization] [ner:misc] new contact_lens_polymer several central nervous system cardiovascular therapeutics plus geographic expansion many generic api active pharmaceutical ingredient
continued weakness euro permit [ner:misc] competitor snipe couple old product
sale animal_health_and_ag_product due order_timing weak sale [ner:date] cause plant_outage
continue see energy feedstock_cost_pressure_profitability segment although expect see moderate later [ner:date]
natural gas_energy_cost animal_health ag_and_specialty_operation cost [ner:money] [ner:date] compare [ner:date]
see specialty_chemical fine chemical experience slowness product sell segment coating photographic plastic telecommunication_market result general slowdown industrial market
segment also include product drop
offset ship [ner:number] new product [ner:date] development_facility book well [ner:date]
[ner:date] board director meeting [ner:number] topic expansion lab phase_-_ii_expansion tech_center well expansion pilot_plant_facility
look_out full [ner:date] know overall internal growth_rate target [ner:number] human_health [ner:number] bioscience earnings growth [ner:percent] great
continue make progress reposition company life_science_market
top line_growth will drive new product service accelerate drug_discovery development manufacturing process include biomanufacturing anything help customer get therapeutics patient fast
target growth_area include cell media research biotherapeutic human cell base bioassay lead_optimization [ner:organization] [ner:organization] lal_endotoxin_product global expansion generic market niche_generic_product_portfolio combine broad partnership innovative pharmaceutical customer
investment r&d will continue priority fuel organic growth
everything connect unique technology_platform technical capability
lastly want mention announce [ner:date] [ner:person] cfo will retire [ner:date]
[ner:person] [ner:date] senior vice_president corporate_development will replace [ner:person] [ner:person] [ner:date] join q&a [ner:person] executive vice_president chief_operating_officer
operator will [ner:date] open call q&a
okay good morning
[ner:person]
get start know turn_over [ner:person] would like say couple word
would like welcome [ner:organization] [ner:date]
senior vice_president chief_financial_officer
begin would like remind every everyone conference_call [ner:date] hold [ner:date] hold term safe_harbor_disclaimer
disclaimer cover fact discussion might contain content constitute forward look statement within [ner:organization] safe_harbor_provision private securities_litigation_reform_act rule_3b [ner:misc]
although statement represent management good judgment [ner:date] statement involve risk uncertainty could cause result differ materially company expectation
conference_call will [ner:date]
will begin business_highlight [ner:person] follow question_-_and_-_answer_session
request ask [ner:number] question time will honor request [ner:number] clarification require
replay conference_call will available beginning [ner:date] end business_[ner:date] call [ner:number] domestic international
webcast also available website www.cambrex.com
please click investor_relations_button
would like turn meeting [ner:person] chairman chief_executive_officer
okay thank [ner:person]
think recover [ner:number] apologize irritable
well easy quarter see press_release mostly drive dramatic slowdown sale [ner:organization]
specialty fine_chemical_sector addition low demand customer think work_off excess inventory
also continue reactor_problem [ner:number] facility result high cost low throughput poor yield
addition cause shortage product could sell
like everyone else impact foreign exchange although will become less less factor go forward
area invest hold_up quite well specifically [ner:organization]
human_health_area continue see robust pipeline new project big pharma emerge innovator actually [ner:date] project double compare [ner:date] [ner:date]
sale continue increase product like [ner:organization] [ner:misc] therapeutics coronary disease high blood_pressure cancer_product diabetes
also see like delay cause [ner:organization]
actually [ner:number] mention [ner:organization] [ner:date] seem become common occurrence report weak euro put price_pressure old product pull_down sale_growth
[ner:date] [ner:location] sale [ner:percent] close [ner:percent] adjust foreign exchange will get detail
acquisition [ner:organization] account half improvement will talk thing go_on base_business
strong performance cell media endotoxin_detection_product
also new product help_out quite bit several new cell_system instance_caco_-_2_cell use new drug_screening chondrocyte cartilage adipocyte fat_cell adult stem_cell continue well
addition introduce [ner:number] new cell base bioassay reportalight reporter_gene_assay vialight_[ner:organization] chemiluminescence_test microbial detection new elisa enzyme link assay adipocyte fat_cell
cell_therapy new emerge technology many know strategic area [ner:organization] [ner:date] growth start supply_service [ner:number] new cell_therapy_application
keep tight control cost spending lay
also good environment add key r&d_and_sale_person mainly fill open position
[ner:duration] [ner:date] add [ner:number] person r&d [ner:number] person sale marketing cost_increase take_on advance increase sale
opening largely fill although will add person time time support many new growth_program need
look ahead actually look back little bit
internally say [ner:date] enter industrial manufacture recession demand traditional specialty_fine_chemical_area will continue weak think probably well [ner:date] cause pardon over-correction customer inventory
think see really bad contraction
say excited prospects [ner:misc] active pharmaceutical_ingredients manufacture arena small molecule bio-therapeutics
see strong demand api generic pharmaceutical company big pharma product clinical trial emerge pharma small molecule bio-therapeutics
also contract_r&d supply small quantity process_development remain quite strong
support growth invest high return investment_project present board directors [ner:date]
[ner:ordinal] add cgmp_capacity [ner:location] [ner:location] manufacturing control substance
report early put place [ner:organization] procedure install approve
active ingredient make general purpose_cgmp_pilot_plant
new investment will give dedicated facility make control substance will place [ner:date]
secondly expand key process_bottleneck lal_endotoxin_detection_manufacturing
will expand factor [ner:number] will stream [ner:date]
beyond upgrade r&d_lab
instance [ner:location] [ner:number] go_on
already well phase add capability new tech_center [ner:location]
lastly know add capacity new bio_science_contract manufacture facility [ner:location]
suite [ner:number] will stream [ner:date] suite [ner:number] perhaps [ner:date] [ner:date] [ner:date]
lastly would like say look ahead believe give continue drag earnings old business will probably end_up [ner:date] earnings_improvement range [ner:percent] compare [ner:date] versus [ner:duration] [ner:percent]
however new product_growth already see [ner:date] expect earnings return [ner:percent] [ner:date]
okay
[ner:person] think open_it_up q&a
okay actually [ner:person] chief_financial_officer [ner:organization] join [ner:person] chairman ceo well [ner:person] chief_operating_officer president
begin want remind rule conference_call
call hold safe_harbor_disclaimer state discussion might contain context constitute forward look statement within [ner:date] [ner:organization] private securities_litigation_reform_act rule_3b [ner:misc]
although statement represent management good judgment [ner:date] information [ner:date] available statement involve risk uncertainty could cause result differ materially company expectation
conference_call will [ner:date]
will begin introductory statement mr._[ner:person] follow question answer_session
request ask [ner:number] question time though will honor request [ner:number] clarification
replay conference_call will available approximately [ner:date] end business_[ner:date] call [ner:number] domestic [ner:number] international
webcast also accessible website www.cambrex.com
please click investor_relation_button
[ner:date] let turn meeting [ner:person] [ner:organization] ceo
okay [ner:person] thanks
good afternoon
well know issue press_release [ner:date] earnings_shortfall versus analyst consensus_number
analyst follow know [ner:date] low quarter usually [ner:date] give [ner:date]
order make [ner:date] depend strong performance [ner:date]
although point preliminary datum see [ner:date] [ner:date] expect
economy really continue deteriorate [ner:date] compound attack [ner:location] [ner:organization] [ner:date]
know look [ner:location] many headquarters_employee watch horror [ner:date]
understand impact everyone every business country realize business change quite dramatically
forecast use longer apply recheck re-forecast work hard get number get foundation result cause issue release [ner:time]
around number economic cycle see condition severe since [ner:date] except think time happen lot suddenly
[ner:date] order_flow really slow several location fact stop [ner:duration]
order product ready air_shipment delay specifically overseas generic active pharmaceutical ingredient_shipment biotechnology live cell
case customer routine test halt affect reagent_sale
business will pick_up [ner:date] lose entirely
beyond build inventory strike_contingency [ner:number] location
contract settle will correct level inventory [ner:date] [ner:number] will affect operate rate fix cost_absorption
regard [ner:date] take cautious approach
information forecast unreliable point customer conservative
know general uncertainty economic climate will [ner:date]
say expect revenue improve [ner:date] especially bioscience_and_human_health_segment
point somewhat uncertain exact mix human_health part reason little bit cautious sure exactly [ner:date] impact will margin
continue push aggressively cost_containment target_savings [ner:money] pre-tax [ner:date] part will come sg&a discretionary spending part rationalization poorly perform product_line underutilize facility
base see however specific action take new product know grow product good growth_prospects expect good [ner:date]
expect life_science_business continue strengthen together cost_reduction mention minimum improvement specialty fine_chemicals instance_energy raw material already come reach double digit_growth earnings [ner:date] even exclude effect fas [ner:number] goodwill_amortization_accounting
lastly would like say [ner:organization] [ner:date] [ner:organization] formally approve proceed new line credit least [ner:money] time reaffirm management authority repurchase [ner:number] share [ner:organization]
say think [ner:date] operator open floor question
thank [ner:person]
present [ner:time] skeregy_side basically [ner:number] business want twice
[ner:organization]
go give quick overview talk division jump straight healthcare
market_capital [ner:number]
diversify global developer manufacturer reseller security_and_inspection_system medical monitoring anaesthesia_system oximetry health_service [ner:organization]
[ner:number] research_analyst [ner:person] [ner:person] [ner:person] [ner:person]
book value approximately [ner:money] share strait_organic_growth successful integration [ner:number] acquisition
primarily semi-conductor_company
make [ner:misc] distinguish move fast value add strain go play broad industrial segment afraid jump end_product like demonstrate healthcare security_area
chart give idea cagr [ner:percent] guidance [ner:number] [ner:number] [ner:date]
break [ner:date] segmentation though [ner:duration] start segment business [ner:number] segment [ner:organization] security optoelectronics
earnings_call [ner:ordinal] announce time give segmentation
experience management_team
pretty much decentralize [ner:organization] run separately
[ner:organization] consolidate corporate level
thing security opto
group organize [ner:number] division [ner:misc] system security [ner:organization] [ner:organization]
quickly [ner:organization] [ner:duration] optoelectric manufacturing_experience
primarily start_off
group comprise [ner:number] operate company trade_name
manufacturing_capability [ner:location] [ner:location] [ner:location] [ner:location] [ner:location] [ner:location]
strong get design capture addition outside revenue [ner:number] tell the_street [ner:date]
[ner:date] [ner:number] [ner:date] [ner:organization] [ner:organization]
quickly [ner:organization] leader multi-billion_dollar worldwide security_market
vertically integrate security_provider
key product baggage parcel inspection baggage cargo vehicle_inspection person screen
healthcare diversify global developer manufacturer seller medical device include patient_monitoring anaesthesia_equipment pulse_oximetry medical service
approximately [ner:number] patient monitoring_machine sell [ner:duration] [ner:date] [ner:number] anesthetic machine since inception sell globally
approximately [ner:number] employee globally office [ner:number] country establish global brand_name [ner:organization] monitoring [ner:person] anaesthesia dolphin oximetry
group_highlight [ner:number] consecutive quarter profitability since acquisition [ner:organization] [ner:date]
positive cash_flow
complete [ner:number] acquisition since [ner:date]
revenue group approach [ner:money] fiscal [ner:date] growth_strategy will touch later organic growth acquisition complementary technology company
revenue_chart
outside [ner:organization] medical business comprise mostly oximetry osteoporosis_equipment
revenue [ner:number] [ner:date] [ner:date] [ner:number]
[ner:date] will [ner:duration] full integration revenue approximately [ner:money] mention think say couple meeting intention grow internally acquisition [ner:duration]
[ner:organization] get pretty intact team buy [ner:organization] [ner:organization] post-divestiture [ner:organization]
[ner:person] run [ner:organization] patient monitoring blease_new_acquisition acquire [ner:location]
[ner:person] run [ner:organization] [ner:person] run global sale
global presence
distribution datex_sale [ner:location] [ner:location] [ner:location] [ner:location] [ner:location] [ner:location] [ner:location] distribution approximately [ner:number] country
distribution_office [ner:location] [ner:location] [ner:location]
manufacturing [ner:location] [ner:location] [ner:location] [ner:location] joint venture [ner:location] logistic center [ner:location] [ner:location] [ner:location] [ner:location]
r&d spread mostly [ner:location] aggressively move [ner:location]
[ner:number] person [ner:location] back end r&d will monitor also r&d_center [ner:location] anaesthesia_machine
person ask medical
will give chart medical security
establish company [ner:date] provide turnkey_manufacturing medical device [ner:organization] [ner:organization] [ner:organization] [ner:organization] [ner:organization] many [ner:misc] base
[ner:date] acquire unique product_line call arrestone oximetry_business
[ner:date] acquire osteometer
[ner:date] go respiratory gas_analysis_product_line
[ner:date] launch dolphin compatible core_sens anticipation key banquet come lose happen [ner:date] [ner:date] [ner:date]
[ner:date] acquire [ner:organization] [ner:organization] [ner:date] acquire [ner:organization] anaesthesia_company compliment monitor
organize [ner:number] function monitoring [ner:organization] [ner:person] anaesthesia call medical solution oximetry [ner:organization] med datum osteoporosis
will endure monitoring majority business operative market_overview
monitoring_business customer hospital especially tend mean top end hospital
[ner:number] unit sell [ner:duration] [ner:ordinal] lead brand [ner:location] strong brand_recognition [ner:location] [ner:location] [ner:location] [ner:location] [ner:number] [ner:number] recur revenue call supply accessory will touch
opportunity growth business low actually monitor cross sell bundle product oximetry growth replacement_cycle
[ner:location] customer hospital surgery_center clinic
competition [ner:organization] [ner:person] monitoring also [ner:organization] [ner:organization] [ner:person] low end [ner:location]
install basis also large [ner:number] unit install strong [ner:date] strong brand_recognition [ner:location] [ner:location] former [ner:misc] block
print [ner:location]
talk [ner:ordinal] continue rest business [ner:date] plan enter [ner:location]
opportunity [ner:misc] market [ner:misc] market oem_business also cross_selling [ner:location]
monitoring_overview quickly global brand_recognition [ner:number] unit sell globally [ner:duration] global sale service_coverage blue chip_customer_base
company will internally mention word open architecture_platform monitor strong product_development commit r&d
tell street [ner:duration] increase investing industry_peer r&d
approximately r&d run [ner:number] annualize
[ner:date] think [ner:number] plan continue [ner:duration] catch_up
opportunity cut_thing_back percent_point [ner:number]
product_monitoring_portfolio galimetry big spend
introduce [ner:date] [ner:location] well receive
anaesthesia delivery_ventilation overview company establish [ner:date]
specialist design management distribution anaesthesia_system range low mid-high level_anaesthesia_system critically ventilation_product lead supplier oem_product individual anemia_component
new family call [ner:person]
also oem_part accessory business sell oem
medical datum_solution_business divide call [ner:number] different segment oximetry competition medical core masimos [ner:misc] [ner:organization]
pioneer [ner:number] digital l_oximetry_technology
also complete line_-_up compatible remote analog_sensor big opportunity [ner:organization] compatible already oem_business [ner:organization]
launch [ner:date] true link oximetry_product support [ner:organization] [ner:number] unit
[ner:organization] ambulatory blood_pressure_monitoring dominant player [ner:number] monitor sell globally
basically gold_standard
go somebody go look ambulatory blood_pressure_monitoring [ner:organization] product buy
competition suntract [ner:organization] [ner:person]
opportunities gold_standard
want use name also want capture low hang fruit look low cost_manufacturing go back low end
med datum think big growth_opportunity
competition eresearch [ner:organization] covenance
[ner:number] trial participate phase phase [ner:number] phase [ner:number]
opportunities develop market [ner:location] [ner:location] new [ner:organization] ecu_testing basically become requirement
come_up new drug unless ecu_testing
quickly touch oximetry basically opportunity give idea install unit [ner:organization] potential user razor_blade [ner:number] oximeter [ner:date] may call yet
since launch new beginning
think capture big portion market though go take little time medical convert_it_over
installed base mean potential razor_blade_business [ner:number] installed base
also make deal distributor call [ner:organization] [ner:duration] great job penetrate [ner:location]
product digital completely front end back end [ner:number] unique product_differentiation get
[ner:organization] start [ner:date] ecg_measurement_interpretation drug_trial
post-ecg study conduct [ner:date] complete [ner:number] trial market_size approximately [ner:money] ecg_core_lab_testing [ner:date]
big guy marketplace eresearch [ner:percent] market
market_share [ner:percent] believe definitely [ner:duration] will double digit throughout
internally predict [ner:percent] [ner:duration] portion business
though small think really grow business back_-_end strengthen [ner:location] even make cost effective
ambulatory blood_pressure [ner:number] unit globally sell
market_leader
[ner:percent] clinical research
dominate international [ner:location] idea basically capture low side_product manufacturing_strength go back get top end low end
pulp_and_development_opportunity
expansion [ner:misc] market
[ner:location] [ner:location] horizon sale manufacturing r&d
mention already [ner:organization] [ner:location] [ner:location]
plan look market focused grow business
strategic_partnership acquisition must
look acquisition complimentary technology company
also look low acuity_monitor
against [ner:organization] high end_business
want look low acuity_monitor
develop internally maybe strategic partnership go call independent surgery_center doctor office
[ner:organization] strong ethnical presence lot industry_press also wireless capability look [ner:location] also home_care growth_opportunity
lastly introduction anesthesia [ner:location]
plan get go touch [ner:date] digest get
growth_strategy capture_replacement_-_cycle_business monitoring cross_sell_oximetry_sensor basin_monitoring install base leverage_revenue_growth supply accessory
every time sell [ner:misc] [ner:percent] supply accessory
even default business [ner:number] [ner:money]
plan grow
focus onto kind area go enter cable special monitoring_cable oximetry already accessory supply compliment put product_line
grow anesthesia_business [ner:location] [ner:misc] side develop presence low acuity_monitor globally
summary already monitoring acquire anesthesia bundle many place non-u.s. go hand hand many tender anesthesia monitoring go together
get ambulatory blood_pressure_monitoring gold_standard
get medical datum_solution use talent able grow business clinical trial
oximetry perfect razor_-_blade_fit product_line
osteometer talk much couple_[ner:number] product_line go continue rest growth_opportunity
hg_expansion low acuity_monitoring supply accessory [ner:location] home_care area go look growth
anesthesia [ner:location] must telemedicine home_care
thank much
open question
thank [ner:person]
would like thank [ner:person] invite conference actually [ner:ordinal] time [ner:number] [ner:duration]
actually get_my_wife_up could enjoy [ner:misc]
hope able deal well
go start_-_off everyone go read sure
[ner:date] first would like welcome everyone take_the_time_out listen chairman ceo [ner:organization] [ner:person] cfo give highlight company [ner:organization] lpnt
like welcome everyone webcast
would like touch point significant point
[ner:ordinal] [ner:number] page handout talk really happen [ner:person] will talk significant thing go industry affect company financial operationally well
[ner:ordinal] unique company committed pure play volume like non-urban still good old role_boy focus_on focus hospital typically market see last bullet_point sole community_provider acute care [ner:number] [ner:number] market
fix [ner:number] say [ner:duration] county [ner:location] [ner:location] [ner:person] couple [ner:number] person [ner:number] compete hospital
buyer seller process sell hospital believe announce [ner:date]
committed community improve quality care breadth service create cash_flow drive value shareholder
see found company give small amount amount small [ner:percent] [ner:percent] share company retirement_plan [ner:organization] allocate_and_motivate_we_employee_out field [ner:number] employee participate equity motivate way
[ner:date] make significant acquisition [ner:number] work_on good part [ner:duration] acquire [ner:organization] rural hospital albeit [ner:number] facility acute care_facility market
take geographically economically diversify company
live call hi five absolutely critical successful delivery healthcare especially rural community
unique competition power manage care either take provide benefit great relationship physician
see wall_street_perspective focus base core asset essentially expand scope quality care patient
serious quality think watch go_on [ner:organization] [ner:location] president recent bill focus choice get pricing_/_quality communicate consumer well control healthcare_cost responsibility typically number [ner:number] [ner:number] employer market provide good quality_care market typically market person live market leave community get healthcare adequate position service market
therefore tactic recruit recruit recruit physician [ner:person] will go expand service grow volume invest new service make sense
lot analysis community person go get certain service set_out priority capex discipline put together business_plan focus return invest capital [ner:organization]
operate company
[ner:date] yes double size company
create enormous growth [ner:duration] asset non-profit hospital capex will spin_in manage well loss_interest medical staff
tremendous opportunity great success [ner:ordinal] thus acquire province [ner:date] acquire [ner:number] large acquisition [ner:location] [ner:location] [ner:location] [ner:location] [ner:date] tremendous opportunity growth go forward
obviously build anything deliver care without great relationship [ner:misc] physician integrate within community
anything hospital build order physician
know employee live breathe provide structure clinical expertise technology support physician practice medicine obviously priority
employee participate equity [ner:organization] visible motivation
focus quality process_improvement give good workplace competitive salary_benefit
another key element hi five
number [ner:number] number_[ner:number] usually county_education_system hospital large employer extremely involve community highly incentivise employee involve community
infact kid go school show_up [ner:date] grocery_store together pump gas employee physician relation employer community important will say physician recruit number_[ner:number] lose physician community age retirement number [ner:number] fully integrate position family community
get medical staff community_leader involve recruit physician community high retention_rate physician well national average [ner:person] will talk detail
obviously physical responsibility think will find [ner:organization] vote [ner:duration] row institutional investor transparent company
provide information high level detail right thing [ner:percent] business government_business highly regulate need open everybody go_on absolutely critical
show [ner:date] go [ner:number] hospital [ner:date] [ner:number] go [ner:number] [ner:number] hospital course [ner:duration] time
go [ner:number] state significant amount revenue [ner:location] [ner:location] [ner:number] state pretty balanced exposure throughout country
province bring lot hospital large western area good reimbursement high population_growth
instance [ner:misc] many many person move [ner:location] across border [ner:location] suite credit retirement_fund sell home building live much cheap cost beautiful beautiful area could go point strategically create lot internal growth great market
go asset_sale
leverage
focus will de-leverage announce [ner:number] asset_sale jv_money go_on float around [ner:location]
person approach give anything away size company means think grow fast get discipline get acquisition spend money acquire [ner:money] worth revenue [ner:organization] correct
sorry [ner:money] worth additional revenue [ner:organization] acquire [ner:number] hospital
try balance integration_risk asset_sale course acquire another company asset make absolutely sense
identify close finalize sell [ner:number] [ner:date]
course [ner:date] will buy [ner:number] hospital [ner:organization] tremendous opportunity
hospital ignore significant decline medical staff money invest technology
already bring someone board work medical staff focus capital need bring get involved expand medical staff
enormous growth [ner:date] [ner:date] hospital will drive
committed
lot person challenge province_transaction
take perspective sell [ner:number] hospital acquire [ner:number] great growth_opportunity selling [ner:number] growth_opportunity think wise decision
commit transaction will happen
summery operate company will acquisition [ner:date] except [ner:organization] will spend significant capex new service money ever recruit physician market get volume return money investment province [ner:organization] [ner:location] [ner:location] sorry [ner:location] [ner:location] hospital hospital [ner:location] [ner:location] large facility will regional referral center
hopefully give flavor strategy update company
[ner:person] go get significant financial highlight think everyone mind understand guidance [ner:date] go [ner:date] [ner:date] guidance person go significant growth go growth growth [ner:date] pretty good growth [ner:date] closely [ner:money] eps thing [ner:date] blow_it_out [ner:duration] think whole industry see somewhat backing volume medicate problem drive bad debt especially [ner:location] [ner:organization] [ner:location] [ner:location] result katrina pretty big impact many company
[ner:person]
thank [ner:person] much
go go quickly item [ner:date] question come_up [ner:number] question get call relate financial information
[ner:number] item please note file [ner:number] [ner:date] file [ner:number] would show give description pro forma information relate province_transaction would occur [ner:date] also [ner:location] occur [ner:date] also [ner:organization] would occur also [ner:date] would like refer much would also like remind everybody [ner:person] state start [ner:date] [ner:number] hospital whole lot activity end_up [ner:date] [ner:number] hospital
also want talk briefly physician_recruiting [ner:person] state area go heavily focus [ner:number] great divisional ceo hospital_ceo focused [ner:date] meet together hospital_ceo divisional operation_person alongwith hospital_ceo discuss start heavily planning position_recruiting retention will meet like say [ner:duration] [ner:location]
will keep constantly inform [ner:set] review [ner:number]
also want quickly talk [ner:organization] [ner:person] state [ner:misc]
[ner:organization] pretty much discuss everything predominantly recent bill key item believe inpatient rehabilitate state [ner:percent]
good news evaluate [ner:date] budget however give lot credibility point time pass
number thing go impact would impact hospital [ner:number] significant obviously period [ner:duration] able put cost_report bad debt relate deductible amount will phase_out [ner:duration]
[ner:misc] [ner:person] briefly touch [ner:organization] little bit
still see challenge particularly denial come_up particularly individual try get roll [ner:misc]
see process get little bit difficult number state
although state start see surplus still see much change [ner:location]
[ner:number] item also note also discuss think [ner:number] particular hospital several folk tell state [ner:location]
[ner:location] change
sort dish_payment normally give
increase rate
suppose little neutral
majority hospital except [ner:number] reason [ner:number] get [ner:number]
high [ner:misc] base [ner:location] [ner:location] [ner:location] hospital also [ner:percent] see impact
[ner:number] come
bad debt talk [ner:number] use company use outside service look credit_card_opportunity individual apply well hospital roll_it_out
pilot_program [ner:date] see improvement [ner:number] basis_point little [ner:number] basis_point_improvement
go roll_that_out [ner:number] hospital [ner:date] will take little bit time see come play go look remainder hospital roll_that_out throughout [ner:date]
go continually concentrate upfront collection bad debt always know much industry_issue
give little bit_[ner:date] want get much involved preliminary amount preliminary review see [ner:date] pleased see [ner:date] stand point
will take place [ner:date] [ner:person] state [ner:date] sort rebase_[ner:duration] go get back basics get back high [ner:number] refocus get much reconfirm strong hospital strong market
okay
get [ner:duration] leave [ner:number] significant thought important thought culture company family orient retain top person industry
[ner:ordinal] [ner:person] think see congratulation [ner:ordinal] child bear
fortunate enough [ner:ordinal] grandchild gorgeous little girl [ner:date] bear fact son work investment_banking [ner:organization] [ner:person] [ner:person] key help create strong work_ethic [ner:number] working [ner:organization]
importantly little bit culture importantly prove volume bad debt course [ner:duration]
[ner:date] eps multiple multiple [ner:organization] low end range [ner:date] [ner:person] community_hospitals back know track [ner:person] wonderful great group asset tremendous reputation industry focus rural hospital
goal get back [ner:person] multiple
study [ner:person] look upside opportunity [ner:date] grow volume improve bad debt
thank much
[ner:misc] answer_session hold conjunction call

thank
good morning
well [ner:ordinal] would like thank [ner:person] organizer conference give opportunity come talk [ner:person] [ner:date]
follow [ner:person] [ner:date] know significant exciting development [ner:date] specifically acquisition [ner:organization]
[ner:date] look like minority presentation least [ner:person] would complete without obligatory safe_harbor_statement
would direct please consider forward look statement might make [ner:date] presentation within context also within context [ner:duration]
[ner:person]
medical product_company publicly trade [ner:location] also [ner:location] [ner:date] fab subsidiary
[ner:duration] work naturally occur biomolecule call hyaluronan hyaluronic acid [ner:date] would refer ha
think fair say fab [ner:person] recognize innovative developer differentiate product
product cover several medical discipline orthopedic joint health advanced wound_care ophthalmology veterinary medicine general surgical application aesthetic dermatology
also believe recognize [ner:person] high quality innovative manufacturer product
stage development [ner:organization] fab_acquisition
well simple answer technology expand product_portfolio
lot
technology_perspective [ner:number] well patent protect powerful basic technology fab [ner:location] [ner:organization] will talk little bit [ner:duration]
within [ner:person] talk quite time expand develop commercialization_office [ner:location] fab_location [ner:location] well commercialize staff fulfil goal nicely
human capital_perspective combination [ner:number] organization [ner:number] little focused research [ner:number] little focused development additive
finally product_portfolio technology also research_program additive lot would think [ner:ordinal] glance
let talk little hyaff_technology_success
essentially react ha_molecule hyaluronan insoluble
allow processing material solid form make fiber film sponge tube even microsphere
good portion product date weave non-woven mesh ha use amount fairly standard textile_technology
however move forward see could potential myriad application technology ha alone also ha combination biomaterial pharmacologically active entity
will skip slide interest time
[ner:ordinal] basic technology acquire fab_acquisition autocrosslink polymerization produce viscous ha_gel
would also point_out [ner:person] crosslink_technology basis monovisc [ner:location] elevess hydrelle product_franchise
actually powerful [ner:date] combination chemical_modification_technology give good leg able solve lot thorny formulation_problem develop new product
word vision [ner:person] [ner:date] fab_acquisition
see inventor developer commercialize agent innovative therapeutic product tissue_protection healing repair
move forward primary area focus go joint health orthopedic advanced wound_care surgical application paradigm cover continuum patient care palliative protective restorative
let switch gear little bit look revenue_growth [ner:location] include fab
apologize [ner:duration] datum [ner:duration]
will announce [ner:date] year_-_end result [ner:date] possible [ner:date] view [ner:date]
[ner:number] thing note [ner:ordinal] see tiny yellow dusting top represent aesthetic dermatology_product
think significant upside company product get adopt expand distribution worldwide see main driver certainly [ner:person] joint health_area will continue case [ner:date]
say joint health mostly talk product treat osteoarthritis call viscosupplementation_product injection hyaluronic acid
see substantial market worldwide market grow take look [ner:location] single large market probably [ner:number] product [ner:date] approve sale [ner:location]
product target [ner:duration] pain_relief multiple injection_product
[ner:location] product market [ner:organization] [ner:organization] product [ner:organization] [ner:number]
rest product try accomplish goal [ner:number]
[ner:number] single injection_product call synvisc_-_one release [ner:date] start make quite impact marketplace
move forward [ner:date] look [ner:person] see [ner:number] thing
[ner:number] believe market shift single injection_product
also believe will place multiple injection_product would seem [ner:number] injection_product may lose luster unless efficacy_,_safety_or_real_cost_gain_implication
shift single injection_product put pretty good stead [ner:person] product call monovisc receive pretty good attention [ner:location] [ner:date] [ner:location]
status product [ner:location] move [ner:organization] [ner:organization]
take modular approach
submit clinical module [ner:date] expect will get approval [ner:date]
let take look milestone achieve joint health_franchise good revenue_growth
talk progress monovisc
would bring attention [ner:number] point
[ner:ordinal] generation_product development call cingal
ha active therapeutic molecule incorporate
intend bring clinic [ner:date]
run minor technical problem importantly major distraction regard fab_acquisition
still move forward product rationalize total product_portfolio maybe original schedule intend
take long term_view couple important thing talk
[ner:ordinal] intent take monovisc directly commercialize [ner:location] sale_force
would add relevant fab_product get approve [ner:location] put also bag person
fab successful develop cartilage_generation_product available [ner:location] hyalograft_c_and_hyalofas_product mention
long term_strategy product [ner:date] [ner:date] develop
totally clear will require bring [ner:location] juncture
[ner:location] [ner:location] fab locate pretty sophisticated cell_biology_and_cell_processing_facility
facility call tissue_test_product make
[ner:number] product use polygase_cell [ner:ordinal] hyalograft_c incorporate chondrocyte hyaff_matrix [ner:number] laserskin_autograft_and_hyalograft_-_3d_matrix incorporate keratinocyte fiber_black hyaff_matrix
wound_care_application will talk little bit [ner:duration]
look hyalograft_c number patient implant follow_up fairly significant period time excellent result
really time go result presentation [ner:date] successful product date
essentially show process use biopsy take cell isolate concentrate seat matrix
matrix develop implant back within [ner:duration]
[ner:number]
another product portfolio recent product ce mark something call hyalofas
essence [ner:number]
see hyalofas_matrix make ready implantation
will let read slide essentially hyalofas take bone_marrow_acid_msd incorporate therein incorporate hyaff_matrix [ner:number]
rationale hyalofas list
[ner:number] thing want point_out spend fair amount time fab_develop_treatment_regimen paradigm look repair cartilage_lesion forth
existence hyalofas hyalograft_c. really complementary
use treat [ner:number] different size_defect
think comprehensive portfolio cartilage_repair
move advanced wound_care really lot time spend
takeaway fairly extensive portfolio product treat various aspect complex wound
go focus_on top pyramid skin_substitute
mention hyalograft_3d_autograft
hyaff_matrix seat fiberglass see matrix cell attachment progress
product portfolio laserskin_autograft
hyaff_matrix time seed high metric_time silicon_layer place top
outer layer use adequate wound_bed would use product combination
autograft initially [ner:number]
cartoon depict product make essentially start biopsy various cell_site separate
similar hyalograft_c
move concentrate cell seed cell matrix return back doctor implantation patient
will skip give idea portfolio product fab
want mention product commercial product [ner:number] program development
hyalobarrier_gel post-op adhesion_prevention_product use general pelvic surgery
large large amount clinical datum available product
quite successful [ner:location]
start make headway revenue [ner:location]
evaluate would take bring product [ner:location] likely randomized clinical trial
item note particular slide hyalospine
use prevent postoperative adhesion spinal surgery
several product [ner:date] market
[ner:number] quite different take innovative approach
status basic preclinical pilot_study [ner:date] product [ner:location]
let move [ner:date] little bit financial datum
revenue see nice growth
able grow gross margin reasonably well
bottom line eps show growth certainly lot investor expect
[ner:number] issue impact eps_growth construction new manufacturing_plant corporate center
build [ner:location] [ner:location] process [ner:date] validate will soon move garner [ner:organization]
run facility really somewhat expensive
way would
need capacity automation build new plant also plan transfer lot [ner:organization] [ner:location] manufacture
balance_sheet [ner:duration] [ner:date] reasonable cash_position even fab_acquisition little debt
acquire fab [ner:date] balance_sheet will release [ner:duration] will considerably different [ner:number]
move forward [ner:date] main corporate goal hope achieve
[ner:ordinal] foremost approval monovisc [ner:location] [ner:ordinal] launch_monovisc commercialization_arm [ner:location] continue worldwide commercial expansion [ner:organization] monovisc network distribution_partner additional new regulatory approval new country [ner:ordinal] fab_acquisition integration several task well way [ner:duration] [ner:ordinal] achieve final regulatory approval full manufacturing_status new plant [ner:location] [ner:location] finally increase continue increase revenue_growth maintain profitability least level [ner:date] hopefully reach
thank much attention
thank [ner:person]
[ner:person] mention [ner:person] strong growth operating_profit [ner:date] base high sale service improve gross margin
performance [ner:location] [ner:location] [ner:location] particularly strong
total revenue [ner:date] nok [ner:number] [ner:percent] [ner:date]
currency_movement positive effect [ner:percent] group_revenue [ner:date]
growth revenue drive high sale service [ner:percent] software [ner:percent]
offset slightly low sale hardware fall [ner:percent]
total gross margin increase [ner:percent] [ner:percent] [ner:date]
improvement gross margin drive high proportion service revenue_mix
base increase revenue improve gross margin [ner:organization] grow [ner:percent] nok [ner:number]
finally depreciation_and_amortization_cost fall [ner:percent] [ner:date]
primarily due low capital_expenditure [ner:duration] [ner:date]
improve capital_efficiency [ner:location] ebit grow [ner:percent] nok [ner:number]
will [ner:date] take close look revenue profit development across country operate
start [ner:location] sharp increase profitability [ner:date]
total revenue grow [ner:percent] [ner:money]
product_revenue [ner:percent] drive high sale client relate software
service_revenue [ner:percent] base growth long term_service_contract outsourcing support_agreement
gross margin increase slightly [ner:percent] compare [ner:percent] [ner:date]
increase gross margin base high sale [ner:organization] service proportion revenue_mix
personnel operating_expense flat [ner:date] result low head_count
[ner:date] [ner:organization] [ner:number] full time_employee [ner:location] compare [ner:date]
base high service_revenue low head_count [ner:organization] [ner:location] grow [ner:percent] [ner:date] [ner:money]
will [ner:date] move [ner:location] business also solid growth revenue profitability
total revenue [ner:location] grow [ner:percent] sek [ner:number]
product_sale grow [ner:percent] compare [ner:date] drive high demand public sector_customer
service_revenue grow [ner:percent] [ner:date] high sale consulting contract service
time gross margin increase significantly [ner:percent] compare [ner:percent] [ner:date]
increase gross margin base high hardware_margin increase sale [ner:person] service proportion revenue_mix
solid revenue_growth improve gross margin [ner:location] [ner:organization] grow [ner:percent] sek [ner:number]
continue_on [ner:location]
[ner:location] atea report low sale also low operating_expense [ner:date]
[ner:organization] slightly [ner:organization] [ner:date]
total revenue fall [ner:percent] [ner:date] dkk [ner:number]
product_revenue [ner:percent] strong comparable period [ner:date]
[ner:date] [ner:date] product_revenue grow [ner:percent] base large project_rollout within client audio_/_video_solution
service_revenue increase [ner:percent] base high sale contract service
total gross margin improve slightly [ner:percent] [ner:date] compare [ner:percent] [ner:date] reflect service revenue_mix
[ner:duration] [ner:person] take step reduce staffing_level [ner:location] response low sale
since [ner:date] number full time_employee [ner:location] fall nearly [ner:number]
[ner:date] average number full time_employee [ner:location] [ner:percent] [ner:date]
addition business greatly reduce capital_expenditure [ner:date]
result depreciation_cost fall [ner:percent] [ner:location] compare [ner:date]
low operating_expense offset low revenue [ner:organization] dkk [ner:number] [ner:date] compare dkk [ner:number] [ner:date]
[ner:organization] [ner:location] increase dkk [ner:number] dkk [ner:number] result low depreciation_cost
ahead guidance give last [ner:set] presentation
[ner:location] business continue show excellent growth revenue profitability throughout [ner:date]
total revenue grow [ner:percent] [ner:money]
product_sale grow [ner:percent] base high demand client_hardware particularly within new public sector_frame_agreement
service_revenue [ner:percent] base high sale software_consultant large project_implementation
gross margin increase [ner:percent] [ner:percent] [ner:date] high proportion service revenue_mix
high revenue gross margin [ner:organization] grow [ner:money] compare minus [ner:money] [ner:date]
finally [ner:organization] low revenue profitability [ner:date]
total revenue [ner:percent] [ner:money]
product_revenue increase [ner:percent] [ner:date] service [ner:percent] due large subcontract project [ner:date]
personnel operating_expense grow [ner:percent] [ner:money]
increase primarily due salary_inflation change employee_mix toward high end_consultant
low revenue high operating_expense [ner:organization] [ner:percent] [ner:date] [ner:money]
need put perspective despite decline ebitda_margin [ner:location] remain healthy [ner:percent]
finally word cash_flow
cash_flow operation inflow nok [ner:number] [ner:date] compare inflow nok [ner:number] [ner:date]
see chart atea operating_cash_flow highly seasonal peak [ner:date] negative cash_flow [ner:date] work capital_balance increase low level [ner:duration]
base seasonal pattern [ner:location] aim throughout [ner:date] continuously improve working_capital_balance seasonal period [ner:date]
[ner:person] work capital_balance fall period [ner:date] work capital will positive impact cash_flow [ner:date]
[ner:date] [ner:location] net work capital_balance remain nok [ner:number] [ner:date] reflect high [ner:duration] outstanding compare [ner:date]
conclude summary [ner:date]
will [ner:date] pass back podium [ner:location] provide information profit_improvement_initiative [ner:location] across business go forward


